Drug intelligence / Profile preview

CP103

Development stage: Preclinical
Lead developer: Consegna Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

CP103 is a long-acting injectable (LAI) formulation of the atypical antipsychotic quetiapine, currently in preclinical development by Consegna Pharma. Designed for the treatment of schizophrenia and other psychiatric disorders, CP103 utilizes a proprietary delivery technology to provide a sustained release of quetiapine over a 28-day period. Its mechanism of action involves the antagonism of dopamine D2 receptors and serotonin 5-HT2A receptors, which helps manage both positive and negative symptoms of psychosis. The LAI modality is intended to improve patient compliance and therapeutic outcomes by reducing the burden of daily oral administration.

Other names: quetiapine long-acting injectableQuetiapine 28-dayQuetiapine28-dayQuetiapine-28-day

Targets

DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on CP103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP103.

Explore the full profile